PhD, Louisiana State University
MA, Experimental Psychology, Louisiana State University
Neuropsychological assessment, movement disorders, Parkinson’s disease, Tourette syndrome, Dementia, Stroke, and Attention deficit hyperactivity disorder (ADHD)
Bryan Bernard, PhD, is an associate professor in the Department of Neurological Sciences within the movement disorders section. He received his PhD from Louisiana State University in clinical psychology. He is a trained neuropsychologist and can administer comprehensive neuropsychological testing. In addition, he is trained in Cognitive Behavioral Intervention for Tics (CBIT) and has been providing this service, along with other treatments to children and adults with Tourette syndrome and tic disorders who come to our clinic. He is also certified in clinical hypnosis by the American Society of Clinical Hypnosis and well versed on administering Cognitive Behavioral Therapy and relaxation technique training. In addition, Bernard is also involved in research assessing longitudinal cognitive functioning in Parkinson’s disease (PD) and Fragile X-associated tremor and ataxia syndrome (FXTAS), cognitive effects of deep brain stimulation, MRI correlates of cognition in PD, and the interaction of cognition with balance and gait in premutation carriers with and without FXTAS.
Michael J. Fox Foundation
Neuropsychologist
Clinical and neuroimaging predictors of cognitive decline in Parkinson’s disease
Bakalar Foundation
Neuropsychologist
Biomarkers and Parkinson’s disease
The goal of this pilot study is identify biomarkers for Parkinson’s disease, atypical Parkinsonism, and prodromal Parkinson’s disease using advanced neuroimaging techniques.
NIH/NINDS
K23NS060949
Neuropsychologist
Parkinson’s disease, cognitive impairment, and structural MRI
The goal of this study is to investigate the neuroanatomical substrates of cognitive impairment and dementia in Parkinson’s disease (PD) using neuroimaging (volumetry and voxel-based morphometry).
National Institute of Health
Co-Investigator
Women with the FMR1 Premutation: FXTAS, FXPOI, and Beyond (2 of 6)
Pfizer Pharmaceutical, Inc.
Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil (Viagra) in Parkinson’s disease Men with Erectile Dysfunction